On October 12, 1976, Alvan, George E.; Holstius, Elvin A. published a patent.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Solution containing trimethoprim, sulfacetamide, and polymyxin. And the patent contained the following:
Ophthalmic solutions for the treatment of microbial (especially bacterial) infections containing sulfacetamide (I) [144-80-9], a trimethoprim salt, and polymyxin salt were reported. E.g., an ophthalmic solution contains I 0.50, trimethoprim hemisulfate [56585-33-2] 0.123 g, polymyxin B sulfate [1405-20-5], 1,200,000 units, thimerosal 0.001, NaCl 0.83 g, and water for injection to 100.00 ml. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate
The Article related to trimethoprim sulfacetamide polymyxin ophthalmic solution, Pharmaceuticals: Formulation and Compounding and other aspects.Reference of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia